Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR

BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Restelli, Umberto, García-Goñi, Manuel, Lew-Starowicz, Michal, Mierzejewski, Pawel, Silvola, Sofia, Mayoral-van Son, Jacqueline, Croce, Davide, Rocca, Paola, Crespo-Facorro, Benedicto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/
https://www.ncbi.nlm.nih.gov/pubmed/32648201
http://dx.doi.org/10.1007/s40261-020-00944-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/
https://www.ncbi.nlm.nih.gov/pubmed/32648201
http://dx.doi.org/10.1007/s40261-020-00944-0

Ejemplares similares